19 October 2021
PRESS RELEASE
BioMAdvanced Diagnostics was distinguished and rewarded alongside 4 other companies at the 21st edition of Start West, a flagship event for seed and innovation capital in France, which took place this year in Nantes. 24 projects had been selected from among 60 companies initially applying. At the end of a day filled with pitches in front of the juries of the event, to convince them and to exchange directly with investors, BioMAdvanced Diagnostics received the special prize from the Pays de la Loire Region. More than 250 people, including 71 investors representing 48 investment structures, were present today at this 2021 edition of Start West, an event that since 2001 has supported and rewarded entrepreneurs looking for financing for their technological innovation projects. The company would like to thank the organizers and especially Atlanpole for this unique opportunity.
As a reminder, BioMAdvanced Diagnostics, a BioTech/MedTech start-up from Nantes, a spinoff from the CRTI laboratory (Centre de Recherche en Transplantation et Immunologie, UMR 1064, INSERM – University of Nantes) and from the University Hospital (CHU) of Nantes, which aims to offer companion molecular diagnostic tests and biomarkers in connection with the immune response of patients. On the basis of a common technological base, the first applications will concern: 1) improving the follow-up of patients who have received a kidney or lung transplant, and 2) determining the best drug to administer to patients with ulcerative colitis (UC). These tests are designed to be integrated into standard diagnostic and treatment protocols, easy to use by staff caring for targeted patients. Predictive scores are produced using algorithms based on the combination of signatures from the expression of selected genes and clinical parameters.